Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 17, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Nanobodies – A new Antibody fragment against COVID–19?

A Goldilocks Zone on Earth: Phytoplankton factory in Sea

An early warning sign for the silent killer heart disease discovered

Nanobodies – A new Antibody fragment against COVID–19?
  • BiotechToday
  • World

Nanobodies – A new Antibody fragment against COVID–19?

bioxone January 19, 2021January 19, 2021

Prama Ghosh, Amity University Kolkata

Researchers at the University of Bonn, Germany, have identified and developed novel antibody fragments against the SARS coronavirus-2. These antibody fragments are smaller than classic antibodies and hence are called nanobodies. These nanobodies are better at penetrating the tissues and also can be produced in large quantities. The nanobodies were also combined into potentially particularly effective molecules capable of attacking different parts of the virus simultaneously. Due to their simple structure, nanobodies can also be produced by yeast or bacteria which will be less expensive. Out of dozens of molecules obtained from the blood sample of animals, four of them proved to be effective against coronavirus. Analyses from X-ray structures and electron microscopy showed the interaction spike protein of the virus with these nanobodies. 

The spike protein acts like a velcro fastener which not only helps in the attachment of the pathogen with the host cell but also mediates fusion of the virus envelope with the cell. It is seen that that nanobodies trigger structural changes in the protein before the virus encounters its target cell. This disables the virus from binding to host cells and infecting them. The simple structure of the nanobodies allows the researchers to combine them in various forms to form molecules that can target different parts of the spike protein of coronavirus. The variant demonstrated a high level of effectiveness in cell cultures convincing the researchers that this could be a novel and promising therapeutic option.

Also read:A Goldilocks Zone on Earth: Phytoplankton factory in Sea

Reference: Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged Antibody Bonn University CORONAVIRUS coronavirus therapy COVID antibody COVID–19 nanobodies pathogen SARS coronavirus – 2 spike protein

One thought on “Nanobodies – A new Antibody fragment against COVID–19?”

  1. Pingback: An early warning sign for the silent killer heart disease discovered - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

An early warning sign for the silent killer heart disease discovered

bioxone January 19, 2021

Husna, Amity University Kolkata Cardiovascular disease which includes heart disease and stroke is referred to as a silent killer because many people aren’t even aware that they are at risk, yet it is the number one cause of death globally and causes around 9.4 million deaths each year.  A new Edith Cowan University-led study has […]

heart disease

Related Post

  • BiotechToday
  • World

Non-Invasive Prenatal Test (NIPT) towards breast cancer detection and monitoring!

bioxone October 15, 2020October 14, 2020

Richismita Hazra, Amity University Kolkata Non-Invasive Prenatal Test (NIPT) is a method useful for the determination of chromosomal abnormalities in unborn children or fetuses. Although ancillary detection of occult malignancies upon routine NIPT has been observed and reported by numerous researchers, these studies were not destined for the evaluation of NIPT for cancer detection. IPSec, […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Comeback of tuberculosis- but its drug-resistant now!

BioTech Today July 3, 2021July 2, 2021

Vaishnavi Kardale, Bioinformatics Centre, Savitribai Phule Pune University Tuberculosis is a major health concern in many low and middle-income countries. TB continues to be the top killer infectious disease in the world. In 2019 over 10.0 million people were affected with TB and 1.41 million deaths were attributed to it. TB affects all countries of […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • World

Heparin sulfate: the key to coronavirus infection

bioxone September 18, 2020September 18, 2020

-Arpita Adhikary, Amity University Kolkata It has been observed in the studies that when the SARS-CoV-2 virus infects – Heparin sulfate and ACE2 enter inside the cells. The course of viral entry and successful attachment is quite limpid. Angiotensin-converting enzyme 2 receptors are present on the outer surface of cells that line the lungs. SARS-CoV-2 […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy